|Mr. Gyo Sagara||CEO, Pres & Representative Director||N/A||N/A||N/A|
|Mr. Shozo Matsuoka||Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QA||N/A||N/A||N/A|
|Yukio Tani||Corp. Exec. Officer & Head of Corp. Communications||N/A||N/A||N/A|
|Mr. Hiroshi Ichikawa||Corp. Sr. Exec. Officer and Exec. Director of Sales & Marketing||N/A||N/A||N/A|
|Mr. Isao Ono||Exec. Officer, Director of Corp. Research & Director||N/A||N/A||N/A|
|Mr. Toichi Takino||Sr. Exec. Officer, Exec. Director of Discovery & Research and Director||N/A||N/A||N/A|
|Mr. Toshihiro Tsujinaka||Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director||N/A||N/A||N/A|
|Kiyoaki Idemitsu||Corp. Exec. Officer, Exec. Director of Clinical Devel. & Director||N/A||N/A||N/A|
|Shinji Takai M.D.||Corp. Officer, Head of Medical Affairs & Head of Data Strategy||N/A||N/A||N/A|
|Satoshi Takahagi||Bus. Unit Director for Oncology Bus. Unit, Sales & Marketing||N/A||N/A||N/A|
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and option agreement with Numab Therapeutics AG. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Ono Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of July 1, 2021 is 3. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 2; Compensation: 1.